Pulmonary Embolism Market

Global Pulmonary Embolism Market Size, Trends & Analysis - Forecasts to 2028 By Route of Administration (Oral and Parenteral), By Treatment (Medications, Mechanical Devices, Surgery, Others), By End-User (Hospitals, Specialty Clinics, Homecare, Others), By Region (North America, Asia Pacific, Central and South America, Europe, Middle East and Africa), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare

Format

This report was recently updated on November 16 2024 with the latest and most recent market numbers

Global Pulmonary Embolism Market Size

The Global Pulmonary Embolism Market is estimated to be valued at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion by 2028, to grow at a CAGR of 8.4%.

The market for pulmonary embolism is anticipated to expand steadily over the course of the forecast period as a result of advancements in medical diagnosis, treatment, and healthcare. The leading cause of death in the elderly population is pulmonary disease. A pulmonary embolism causes sudden breathlessness and excruciating chest pain followed by blood clotting in the lungs. There is a critical need for quick treatment mechanisms in the healthcare system due to the rising incidence of respiratory diseases and their direct linkage to pulmonary embolism. The market for pulmonary embolism is expected to have a tremendous global economic impact in the years to come.

An increase in the prevalence of cancer is driving the market for pulmonary embolisms. Patients undergoing chemotherapy or those with a family history of the condition are most at risk; hence the demand for the drugs is expected to increase. As the number of cancer patients rises, the industry is anticipated to grow.

Another significant factor influencing the market growth rate for pulmonary embolism is the increasing cost of healthcare, which contributes to the construction of its infrastructure. One of the main causes of lung diseases, including pulmonary embolism, is long-term smoking addiction. This population base's stress levels have increased significantly as a result of growing urbanisation, industrialization, and mounting work demands. This scenario is anticipated to increase smoking addiction, which would increase the market's potential for sales of pulmonary embolisms globally.

The market for pulmonary embolisms is forecasted to propel as more public and private organisations launch awareness-raising campaigns. High disposable income, rising demand for cutting-edge therapies, and creative solutions are the factors propagating the growth of the market during the forecast period.

Another factor causing the market to grow is an increase in R&D activity levels. This creates favourable opportunities for pulmonary embolisms market to grow. Rising drug approvals and launches will also speed up the market's expansion. For instance, in August 2021, Boston Scientific had announced the initiation of randomized controlled trial for the EkoSonic Endovascular System. The EKOS system's ultrasound technology speeds up thrombolysis, or the breakup of a clot, reducing the time it takes to treat a patient and lowering the required thrombolytic dose, which can lead to better outcomes and a lower risk of bleeding thereby fostering the market growth for pulmonary embolism.

global pulmonary embolism market

Global Pulmonary Embolism Market: By Route of Administration [RoA]

The oral RoA segment accounted for the largest pulmonary embolism market share during the forecast period of 2023-2028. This was primarily caused by the recent approval of several oral anticoagulants.

Global Pulmonary Embolism Market: By Treatment

On the basis of treatment, the pulmonary embolism market is bifurcated into medications, mechanical devices, surgery and others. The medications segment is anticipated to be the largest segment in the market from 2023-2028. Heparin, enoxaparin, or warfarin are common anticoagulant drugs used to thin the blood and stop further clotting from occurring. New-generation oral anticoagulants that have been released by a number of vendors have fuelled the expansion of the global market for pulmonary embolisms.

Global Pulmonary Embolism Market: By End-User

The hospitals segment is anticipated to be the fastest-growing segment in the market from 2023-2028 owing to the easy accessibility of drugs to the patients admitted in hospitals. The medical fraternity has been paying increasing attention on key areas such as pulmonary and cardiovascular health. This factor has further propelled the market growth of the global pulmonary embolism market during the forecast period.

asia pacific pulmonary embolism market

Global Pulmonary Embolism Market: By Region

Geographically, the market is anticipated to remain dominant in North America due to the large number of clinical trials, FDA approvals, and the presence of key market players. In addition, rising prevalence of pulmonary embolism and other respiratory diseases in the region is anticipated to speed up growth.

Asia Pacific is predicted to have rapid growth. The surge in respiratory disease prevalence and growing geriatric population are two important factors that are anticipated to offer the market with lucrative growth opportunities.

Global Pulmonary Embolism Market Share and Competitor Analysis

The paramount competitors covered in the global pulmonary embolism market report include Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, and Johnson & Johnson Private Limited, among others.

Please note: This is not an exhaustive list of companies profiled in the report.

1 STRATEGIC INSIGHTS ON NEW REVENUE POCKETS

1.1 Strategic Opportunity & Attractiveness Analysis

1.1.1 Hot Revenue Pockets

1.1.2 Market Attractiveness Score

1.1.3 Revenue Impacting Opportunity

1.1.4 High Growing Region/Country

1.1.5 Competitor Analysis

1.1.6 Consumer Analysis

1.2 Global Market Estimates' View

1.3 Strategic Insights across Business Functions

1.3.1 For Chief Executive Officers

1.3.2 For Chief Marketing Officers

1.3.3 For Chief Strategy Officers

1.4 Evaluate the Potential of your Existing Business Lines vs. New Lines to Enter Into

2 TECHNOLOGICAL TRENDS

2.1 Technological Adoption Rate

2.2 Current Trend Impact Analysis

2.3 Future Trend Impact Analysis

2.4 Data Metrics on Feed Stocks

3 GLOBAL MARKET OUTLOOK

3.1 Market Pyramid Analysis

3.1.1 Introduction

3.1.2 Adjacent Market Opportunities

3.1.3 Ancillary Market Opportunities

3.2 Demand Side Analysis

3.2.1 Market Drivers: Impact Analysis

3.2.2 Market Restraints: Impact Analysis

3.2.3 Market Opportunities: Impact Analysis

3.2.4 Market Challenges: Impact Analysis

3.3 Supply Side Analysis

3.3.1 Porter’s Five Forces Analysis

3.3.1.1 Threat of New Entrants

3.3.1.2 Threat of New Substitutes

3.3.1.3 Bargaining Power of Suppliers

3.3.1.4 Bargaining Power of Buyers

3.3.1.5 Intensity of Competitive Rivalry

3.3.2 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)

3.3.2.1 Political Landscape

3.3.2.2 Economic Landscape

3.3.2.3 Social Landscape

3.3.2.4 Technology Landscape

3.3.3 Value Chain Analysis

3.3.4 Trend Analysis

3.3.5 Gap Analysis

3.3.6 Cost Analysis

4 GLOBAL PULMONARY EMBOLISM MARKET, BY ROUTES OF ADMINISTRATION (ROA)

4.1 Introduction

4.2 Pulmonary Embolism Market: Routes of Administration (RoA) Scope Key Takeaways

4.3 Revenue Growth Analysis, 2022 & 2028

4.4 Oral

4.4.1 Oral Market Estimates and Forecast, 2020-2028 (USD Million)

4.5 Parenteral

4.5.1 Parenteral Market Estimates and Forecast, 2020-2028 (USD Million)

5 GLOBAL PULMONARY EMBOLISM MARKET, BY END-USER

5.1 Introduction

5.2 Pulmonary Embolism Market: End-User Scope Key Takeaways

5.3 Revenue Growth Analysis, 2022 & 2028

5.4 Hospitals

5.4.1 Hospitals Market Estimates and Forecast, 2020-2028 (USD Million)

5.5 Specialty Clinics

5.5.1 Specialty Clinics Market Estimates and Forecast, 2020-2028 (USD Million)

5.6 Homecare

5.6.1 Homecare Market Estimates and Forecast, 2020-2028 (USD Million)

5.7 Others

5.7.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)

6 GLOBAL PULMONARY EMBOLISM MARKET, BY TREATMENT

6.1 Introduction

6.2 Pulmonary Embolism Market: Treatment Scope Key Takeaways

6.3 Revenue Growth Analysis, 2022 & 2028

6.4 Medications

6.4.1 Medications Market Estimates and Forecast, 2020-2028 (USD Million)

6.5 Mechanical Devices

6.5.1 Mechanical Devices Market Estimates and Forecast, 2020-2028 (USD Million)

6.6 Surgery

6.7.1 Surgery Market Estimates and Forecast, 2020-2028 (USD Million)

6.7 Others

6.7.1 Others Market Estimates and Forecast, 2020-2028 (USD Million)

7 GLOBAL PULMONARY EMBOLISM MARKET, BY REGION

7.1 Introduction

7.2 North America Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.1 By Routes of Administration (RoA)

7.2.2 By End-User

7.2.3 By Treatment

7.2.4 By Country

7.2.4.1 U.S. Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.1.1 By Routes of Administration (RoA)

7.2.4.1.2 By End-User

7.2.4.1.3 By Treatment

7.2.4.2 Canada Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.2.1 By Routes of Administration (RoA)

7.2.4.2.2 By End-User

7.2.4.2.3 By Treatment

7.2.4.3 Mexico Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.2.4.3.1 By Routes of Administration (RoA)

7.2.4.3.2 By End-User

7.2.4.3.3 By Treatment

7.3 Europe Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.1 By Routes of Administration (RoA)

7.3.2 By End-User

7.3.3 By Treatment

7.3.4 By Country

7.3.4.1 Germany Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.1.1 By Routes of Administration (RoA)

7.3.4.1.2 By End-User

7.3.4.1.3 By Treatment

7.3.4.2 U.K. Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.2.1 By Routes of Administration (RoA)

7.3.4.2.2 By End-User

7.3.4.2.3 By Treatment

7.3.4.3 France Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.3.1 By Routes of Administration (RoA)

7.3.4.3.2 By End-User

7.3.4.3.3 By Treatment

7.3.4.4 Italy Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.4.1 By Routes of Administration (RoA)

7.3.4.4.2 By End-User

7.2.4.4.3 By Treatment

7.3.4.5 Spain Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.5.1 By Routes of Administration (RoA)

7.3.4.5.2 By End-User

7.2.4.5.3 By Treatment

7.3.4.6 Netherlands Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.7.1 By Routes of Administration (RoA)

7.3.4.7.2 By End-User

7.2.4.7.3 By Treatment

7.3.4.7 Rest of Europe Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.3.4.7.1 By Routes of Administration (RoA)

7.3.4.7.2 By End-User

7.2.4.7.3 By Treatment

7.4 Asia Pacific Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.1 By Routes of Administration (RoA)

7.4.2 By End-User

7.4.3 By Treatment

7.4.4 By Country

7.4.4.1 China Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.1.1 By Routes of Administration (RoA)

7.4.4.1.2 By End-User

7.4.4.1.3 By Treatment

7.4.4.2 Japan Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.2.1 By Routes of Administration (RoA)

7.4.4.2.2 By End-User

7.4.4.2.3 By Treatment

7.4.4.3 India Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.3.1 By Routes of Administration (RoA)

7.4.4.3.2 By End-User

7.4.4.3.3 By Treatment

7.4.4.4 South Korea Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.4.1 By Routes of Administration (RoA)

7.4.4.4.2 By End-User

7.4.4.4.3 By Treatment

7.4.4.5 Singapore Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.5.1 By Routes of Administration (RoA)

7.4.4.5.2 By End-User

7.4.4.5.3 By Treatment

7.4.4.6 Malaysia Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1 By Routes of Administration (RoA)

7.4.4.7.2 By End-User

7.4.4.7.3 By Treatment

7.4.4.7 Thailand Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.7.1 By Routes of Administration (RoA)

7.4.4.7.2 By End-User

7.4.4.7.3 By Treatment

7.4.4.8 Indonesia Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.8.1 By Routes of Administration (RoA)

7.4.4.8.2 By End-User

7.4.4.8.3 By Treatment

7.4.4.9 Vietnam Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.9.1 By Routes of Administration (RoA)

7.4.4.9.2 By End-User

7.4.4.9.3 By Treatment

7.4.4.10 Taiwan Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.10.1 By Routes of Administration (RoA)

7.4.4.10.2 By End-User

7.4.4.10.3 By Treatment

7.4.4.11 Rest of Asia Pacific Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.4.4.11.1 By Routes of Administration (RoA)

7.4.4.11.2 By End-User

7.4.4.11.3 By Treatment

7.5 Middle East & Africa Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.1 By Routes of Administration (RoA)

7.5.2 By End-User

7.5.3 By Treatment

7.5.4 By Country

7.5.4.1 Saudi Arabia Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.1.1 By Routes of Administration (RoA)

7.5.4.1.2 By End-User

7.5.4.1.3 By Treatment

7.5.4.2 U.A.E. Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.2.1 By Routes of Administration (RoA)

7.5.4.2.2 By End-User

7.5.4.2.3 By Treatment

7.5.4.3 Israel Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.3.1 By Routes of Administration (RoA)

7.5.4.3.2 By End-User

7.5.4.3.3 By Treatment

7.5.4.4 South Africa Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.4.1 By Routes of Administration (RoA)

7.5.4.4.2 By End-User

7.5.4.4.3 By Treatment

7.5.4.5 Rest of Middle East & Africa Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.5.4.5.1 By Routes of Administration (RoA)

7.5.4.5.2 By End-User

7.5.4.5.2 By Treatment

7.6 Central & South America Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.7.1 By Routes of Administration (RoA)

7.7.2 By End-User

7.7.3 By Treatment

7.7.4 By Country

7.7.4.1 Brazil Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.1.1 By Routes of Administration (RoA)

7.7.4.1.2 By End-User

7.7.4.1.3 By Treatment

7.7.4.2 Argentina Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.2.1 By Routes of Administration (RoA)

7.7.4.2.2 By End-User

7.7.4.2.3 By Treatment

7.7.4.3 Chile Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.3.1 By Routes of Administration (RoA)

7.7.4.3.2 By End-User

7.7.4.3.3 By Treatment

7.7.4.4 Rest of Central & South America Pulmonary Embolism Market Estimates and Forecast, 2020-2028 (USD Million)

7.7.4.4.1 By Routes of Administration (RoA)

7.7.4.4.2 By End-User

7.7.4.4.3 By Treatment

8 COMPETITIVE LANDCAPE

8.1 Company Market Share Analysis

8.2 Four Quadrant Positioning Matrix

8.2.1 Market Leaders

8.2.2 Market Visionaries

8.2.3 Market Challengers

8.2.4 Niche Market Players

8.3.4 Rest of the World

8.4 Company Profiles

8.4.1 Abbott

8.4.1.1 Business Description & Financial Analysis

8.4.1.2 SWOT Analysis

8.4.1.3 Products & Services Offered

8.4.1.4 Strategic Alliances between Business Partners

8.4.2 F. Hoffmann-La Roche Ltd.

8.4.2.1 Business Description & Financial Analysis

8.4.2.2 SWOT Analysis

8.4.2.3 Products & Services Offered

8.4.2.4 Strategic Alliances between Business Partners

8.4.3 Mylan N.V.

8.4.3.1 Business Description & Financial Analysis

8.4.3.2 SWOT Analysis

8.4.3.3 Products & Services Offered

8.4.3.4 Strategic Alliances between Business Partners

8.4.4 Teva Pharmaceutical Industries Ltd.

8.4.4.1 Business Description & Financial Analysis

8.4.4.2 SWOT Analysis

8.4.4.3 Products & Services Offered

8.4.4.4 Strategic Alliances between Business Partners

8.4.5 Sanofi

8.4.5.1 Business Description & Financial Analysis

8.4.5.2 SWOT Analysis

8.4.5.3 Products & Services Offered

8.4.5.4 Strategic Alliances between Business Partners

8.4.6 Pfizer Inc.

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.7.4 Strategic Alliances between Business Partners

8.4.7 GlaxoSmithKline plc

8.4.7.1 Business Description & Financial Analysis

8.4.7.2 SWOT Analysis

8.4.7.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.8 Bristol-Myers Squibb Company

8.4.8.1 Business Description & Financial Analysis

8.4.8.2 SWOT Analysis

8.4.8.3 Products & Services Offered

8.4.8.4 Strategic Alliances between Business Partners

8.4.9 Hikma Pharmaceuticals PLC

8.4.9.1 Business Description & Financial Analysis

8.4.9.2 SWOT Analysis

8.4.9.3 Products & Services Offered

8.4.9.4 Strategic Alliances between Business Partners

8.4.10 Johnson & Johnson Private Limited

8.4.10.1 Business Description & Financial Analysis

8.4.10.2 SWOT Analysis

8.4.10.3 Products & Services Offered

8.4.10.4 Strategic Alliances between Business Partners

8.4.11 Other Companies

8.4.11.1 Business Description & Financial Analysis

8.4.11.2 SWOT Analysis

8.4.11.3 Products & Services Offered

8.4.11.4 Strategic Alliances between Business Partners

9 RESEARCH METHODOLOGY

9.1 Market Introduction

9.1.1 Market Definition

9.1.2 Market Scope & SegParenteraltation

9.2 Information ProcureParenteralt

9.2.1 Secondary Research

9.2.1.1 Purchased Databases

9.2.1.2 GMEs Internal Data Repository

9.2.1.3 Secondary Resources & Third Party Perspectives

9.2.1.4 Company Information Sources

9.2.2 Primary Research

9.2.2.1 Various End-User of Respondents for Primary Interviews

9.2.2.2 Number of Interviews Conducted throughout the Research Process

9.2.2.3 Primary Stakeholders

9.2.2.4 Discussion Guide for Primary Participants

9.2.3 Expert Panels

9.2.3.1 Expert Panels Across 30+ Industry

9.2.4 Paid Local Experts

9.2.4.1 Paid Local Experts Across 30+ Industry Across each Region

9.3 Market Estimation

9.3.1 Top-Down Approach

9.3.1.1 Macro-Economic Indicators Considered

9.3.1.2 Micro-Economic Indicators Considered

9.3.2 Bottom Up Approach

9.3.2.1 Company Share Analysis Approach

9.3.2.2 Estimation of Potential Product Sales

9.4 Data Triangulation

9.4.1 Data Collection

9.4.2 Time Series, Cross Sectional & Panel Data Analysis

9.4.3 Cluster Analysis

9.5 Analysis and Output

9.5.1 Inhouse AI Based Real Time Analytics Tool

9.5.2 Output From Desk & Primary Research

9.6 Research Assumptions & Limitations

9.6.1 Research Assumptions

9.6.2 Research Limitations

LIST OF TABLES

1 Global Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Mllion)

2 Oral Market, By Region, 2020-2028 (USD Mllion)

3 Parenteral Market, By Region, 2020-2028 (USD Mllion)

4 Global Pulmonary Embolism Market, By End-User, 2020-2028 (USD Mllion)

5 Hospitals Market, By Region, 2020-2028 (USD Mllion)

6 Specialty Clinics Market, By Region, 2020-2028 (USD Mllion)

7 Homecare Market, By Region, 2020-2028 (USD Mllion)

8 Others Market, By Region, 2020-2028 (USD Mllion)

9 Global Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Mllion)

10 Medications Market, By Region, 2020-2028 (USD Mllion)

11 Mechanical Devices Market, By Region, 2020-2028 (USD Mllion)

12 Surgery Market, By Region, 2020-2028 (USD Mllion)

13 Others Market, By Region, 2020-2028 (USD Mllion)

14 Regional Analysis, 2020-2028 (USD Mllion)

15 North America Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

16 North America Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

17 North America Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

18 North America Pulmonary Embolism Market, By Country, 2020-2028 (USD Million)

19 U.S Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

20 U.S Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

21 U.S Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

22 Canada Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

23 Canada Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

24 Canada Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

25 Mexico Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

26 Mexico Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

27 Mexico Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

28 Europe Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

29 Europe Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

30 Europe Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

31 Germany Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

32 Germany Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

33 Germany Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

34 UK Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

35 UK Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

36 UK Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

37 France Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

38 France Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

39 France Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

40 Italy Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

41 Italy Pulmonary Embolism Market, By T End-User Type, 2020-2028 (USD Million)

42 Italy Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

43 Spain Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

44 Spain Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

45 Spain Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

46 Rest Of Europe Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

47 Rest Of Europe Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

48 Rest of Europe Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

49 Asia Pacific Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

50 Asia Pacific Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

51 Asia Pacific Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

52 Asia Pacific Pulmonary Embolism Market, By Country, 2020-2028 (USD Million)

53 China Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

54 China Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

55 China Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

56 India Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

57 India Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

58 India Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

59 Japan Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

60 Japan Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

61 Japan Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

62 South Korea Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

63 South Korea Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

64 South Korea Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

65 Middle East & Africa Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

66 Middle East & Africa Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

67 Middle East & Africa Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

68 Middle East & Africa Pulmonary Embolism Market, By Country, 2020-2028 (USD Million)

69 Saudi Arabia Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

70 Saudi Arabia Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

71 Saudi Arabia Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

72 UAE Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

73 UAE Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

74 UAE Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

75 Central & South America Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

76 Central & South America Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

77 Central & South America Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

78 Central & South America Pulmonary Embolism Market, By Country, 2020-2028 (USD Million)

79 Brazil Pulmonary Embolism Market, By Routes of Administration (RoA), 2020-2028 (USD Million)

80 Brazil Pulmonary Embolism Market, By End-User, 2020-2028 (USD Million)

81 Brazil Pulmonary Embolism Market, By Treatment, 2020-2028 (USD Million)

82 Abbott : Products & Services Offering

83 F. Hoffmann-La Roche Ltd.: Products & Services Offering

84 Mylan N.V.: Products & Services Offering

85 Teva Pharmaceutical Industries Ltd.: Products & Services Offering

86 Sanofi: Products & Services Offering

87 PFIZER INC.: Products & Services Offering

88 GlaxoSmithKline plc : Products & Services Offering

89 Bristol-Myers Squibb Company: Products & Services Offering

90 Hikma Pharmaceuticals PLC, Inc: Products & Services Offering

91 Johnson & Johnson Private Limited: Products & Services Offering

92 Other Companies: Products & Services Offering

LIST OF FIGURES

1 Global Pulmonary Embolism Market Overview

2 Global Pulmonary Embolism Market Value From 2020-2028 (USD Mllion)

3 Global Pulmonary Embolism Market Share, By Routes of Administration (RoA) (2022)

4 Global Pulmonary Embolism Market Share, By End-User (2022)

5 Global Pulmonary Embolism Market Share, By Treatment (2022)

6 Global Pulmonary Embolism Market, By Region (Asia Pacific Market)

7 Technological Trends In Global Pulmonary Embolism Market

8 Four Quadrant Competitor Positioning Matrix

9 Impact Of Macro & Micro Indicators On The Market

10 Impact Of Key Drivers On The Global Pulmonary Embolism Market

11 Impact Of Challenges On The Global Pulmonary Embolism Market

12 Porter’s Five Forces Analysis

13 Global Pulmonary Embolism Market: By Routes of Administration (RoA) Scope Key Takeaways

14 Global Pulmonary Embolism Market, By Routes of Administration (RoA) Segment: Revenue Growth Analysis

15 Oral Market, By Region, 2020-2028 (USD Mllion)

16 Parenteral Market, By Region, 2020-2028 (USD Mllion)

17 Global Pulmonary Embolism Market: By End-User Scope Key Takeaways

18 Global Pulmonary Embolism Market, By End-User Segment: Revenue Growth Analysis

19 Hospitals Market, By Region, 2020-2028 (USD Mllion)

20 Homecare Market, By Region, 2020-2028 (USD Mllion)

21 Others Market, By Region, 2020-2028 (USD Mllion)

22 Global Pulmonary Embolism Market: By Treatment Scope Key Takeaways

23 Global Pulmonary Embolism Market, By Treatment Segment: Revenue Growth Analysis

24 Medications Market, By Region, 2020-2028 (USD Mllion)

25 Mechanical Devices Market, By Region, 2020-2028 (USD Mllion)

26 Surgery Market, By Region, 2020-2028 (USD Mllion)

27 Others Market, By Region, 2020-2028 (USD Mllion)

28 Regional Segment: Revenue Growth Analysis

29 Global Pulmonary Embolism Market: Regional Analysis

30 North America Pulmonary Embolism Market Overview

31 North America Pulmonary Embolism Market, By Routes of Administration (RoA)

32 North America Pulmonary Embolism Market, By End-User

33 North America Pulmonary Embolism Market, By Treatment

34 North America Pulmonary Embolism Market, By Country

35 U.S. Pulmonary Embolism Market, By Routes of Administration (RoA)

36 U.S. Pulmonary Embolism Market, By End-User

37 U.S. Pulmonary Embolism Market, By Treatment

38 Canada Pulmonary Embolism Market, By Routes of Administration (RoA)

39 Canada Pulmonary Embolism Market, By End-User

40 Canada Pulmonary Embolism Market, By Treatment

41 Mexico Pulmonary Embolism Market, By Routes of Administration (RoA)

42 Mexico Pulmonary Embolism Market, By End-User

43 Mexico Pulmonary Embolism Market, By Treatment

44 Four Quadrant Positioning Matrix

45 Company Market Share Analysis

46 Abbott : Company Snapshot

47 Abbott : SWOT Analysis

48 Abbott : Geographic Presence

49 F. Hoffmann-La Roche Ltd.: Company Snapshot

50 F. Hoffmann-La Roche Ltd.: SWOT Analysis

51 F. Hoffmann-La Roche Ltd.: Geographic Presence

52 Mylan N.V.: Company Snapshot

53 Mylan N.V.: SWOT Analysis

54 Mylan N.V.: Geographic Presence

55 Teva Pharmaceutical Industries Ltd.: Company Snapshot

56 Teva Pharmaceutical Industries Ltd.: Swot Analysis

57 Teva Pharmaceutical Industries Ltd.: Geographic Presence

58 Sanofi: Company Snapshot

59 Sanofi: SWOT Analysis

60 Sanofi: Geographic Presence

61 Pfizer Inc.: Company Snapshot

62 Pfizer Inc.: SWOT Analysis

63 Pfizer Inc.: Geographic Presence

64 GlaxoSmithKline plc : Company Snapshot

65 GlaxoSmithKline plc : SWOT Analysis

66 GlaxoSmithKline plc : Geographic Presence

67 Bristol-Myers Squibb Company: Company Snapshot

68 Bristol-Myers Squibb Company: SWOT Analysis

69 Bristol-Myers Squibb Company: Geographic Presence

70 Hikma Pharmaceuticals PLC, Inc.: Company Snapshot

71 Hikma Pharmaceuticals PLC, Inc.: SWOT Analysis

72 Hikma Pharmaceuticals PLC, Inc.: Geographic Presence

73 Johnson & Johnson Private Limited: Company Snapshot

74 Johnson & Johnson Private Limited: SWOT Analysis

75 Johnson & Johnson Private Limited: Geographic Presence

76 Other Companies: Company Snapshot

77 Other Companies: SWOT Analysis

78 Other Companies: Geographic Presence

The Global Pulmonary Embolism Market has been studied from the year 2019 till 2028. However, the CAGR provided in the report is from the year 2023 to 2028. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Pulmonary Embolism Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the pulmonary embolism market?

The Global Pulmonary Embolism Market is estimated to be valued at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion by 2028.

Who are the major vendors in the pulmonary embolism market?

The paramount competitors covered in the pulmonary embolism market report are Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, and Johnson & Johnson Private Limited among others.

What are the opportunities prevailing in the global pulmonary embolism market?

The opportunities prevailing in the global pulmonary embolism market are the rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities. The projected year is expected to see increased market growth prospects due to factors such as high disposable income, rising demand for cutting-edge therapies, and creative solutions.

What are the major drivers in the pulmonary embolism market?

The primary factor fuelling the expansion of the global pulmonary embolism market is the rise in of advancements in medical diagnosis, treatment, and healthcare. The market for pulmonary embolism is anticipated to grow more swiftly as a result of an increase in the number of patients, rising cost of healthcare, as well as the significant focus on pulmonary health.